Metabolite Identification
Characterize and quantify metabolites with speed, efficiency, and confidence.
Capitalizing on the Benefits of Ion Mobility for Metabolite Identification
Capitalizing on the Benefits of Ion Mobility for Metabolite Identification
Metabolite identification plays a crucial role in drug development, leading to a constant need to evaluate new technologies that can improve data quality or increase efficiencies. The recent example of a multiple sclerosis drug submitted for FDA approval, and the agency’s subsequent refusal to consider the application, illustrates the risk of incomplete characterization of clinically relevant metabolites.
Characterising the Catabolism of Peptides Using Ion Mobility Enabled High Resolution Mass Spectrometry with Mass-Metasite Integration for Data Processing
Characterising the Catabolism of Peptides Using Ion Mobility Enabled High Resolution Mass Spectrometry with Mass-Metasite Integration for Data Processing
The pharmaceutical industry is increasingly exploring biotherapeutic molecules as an alternative to conventional small molecule drugs, with the number of biotherapeutic drugs approved each year continuing to outpace that of small molecule compounds. In response, a growing need exists to characterize and optimize the absorption, distribution, metabolism and excretion (ADME) properties of these diverse biotherapeutics, and with DMPK groups looking to apply similar principles from their small molecule experience to the ADME of diverse biotherapeutics. The challenge is that few software packages available to characterise the clearance and metabolic fate of biotherapeutics. Here, we mine ion mobility high resolution mass spectrometric (DIA) data for the analysis of biotherapeutic drug metabolism using the Mass-MetaSite and WebMetabase software platform for processing.
Development of a Workflow for the Metabolite Profiling and Identification of Peptide-Based Large Molecules
Development of a Workflow for the Metabolite Profiling and Identification of Peptide-Based Large Molecules
Helen Robinson, Ph.D Associate Scientist Covance Laboratories
There is a growing interest within the pharmaceutical industry in the use of large molecules and biotherapeutics as drug compounds. Incubating a variety of known peptides (ca. 25-50 amino acids) with rat kidney homogenate or cryo-preserved rat hepatocytes prior to analysis using a Waters Vion IMS-QTof, Covance shows how UNIFI workflows can be used to interrogate peptide metabolism data.
- 1 of 3
- next ›